Organization | NanoPass Technologies Ltd

NanoPass Technologies Ltd Report issue

For profit Phase 3

Founded: Ness Ziona Israel (2000)

Organization Overview

First Clinical Trial

2007

NCT00558649

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2012

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (5)

bivalent opv (1 trial)

bivalent oral polio vaccine (bopv), type 1 and type 3 (BOPV) (1 trial)

Inactivated polio virus - Enhanced (IPOL) (1 trial)

live oral poliovirus type 1, 2 and 3 (Trivalent oral polio vaccine - Sabin) (1 trial)

polio, inactivated poliovirus vaccine (Salk Vaccine) (2 trials)

Drugs in Other Trials (1)

fluarix (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Poliomyelitis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 6